A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle
Layoffs Hit Biotech Hubs Hard In labs from Boston’s Kendall
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins
Draupnir Bio, a cutting-edge biotechnology company, has successfully raised €12
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
MOST POPULAR
